Currently out of the existing stock ratings of Bill Maughan, 6 are a BUY (100%).

Bill Maughan

Work Performance Price Targets & Ratings Chart

Analyst Bill Maughan works at CANACCORD

Bill Maughan’s has documented 12 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on FATE, Fate Therapeutics at 09-Jan-2023.

Wall Street Analyst Bill Maughan

Analyst best performing recommendations are on DCTH (DELCATH SYSTEMS).
DCTH Delcath Systems FATE Fate Therapeutics IPSC Century Therapeutics NKTX Nkarta 

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

21

$16.68 (386.11%)

18

5 months 17 days ago

0/5 (0%)

$16.4 (356.52%)

Buy

13

$8.68 (200.93%)

25

6 months 8 days ago

1/4 (25%)

$7.59 (140.30%)

245

Buy

20

$15.68 (362.96%)

6 months 8 days ago

1/2 (50%)

$14.59 (269.69%)

36

Buy

18

$13.68 (316.67%)

17

6 months 9 days ago

0/5 (0%)

$12.33 (217.46%)

Buy

14

$9.68 (224.07%)

17

1 years 3 months 3 days ago

0/2 (0%)

$11.06 (376.19%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Bill Maughan?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?